老虎证券

BRIEF-Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Reuters
03-27
BRIEF-Savara Completes Submission Of The Biologics License Application <a href="https://laohu8.com/S/BLA.AU">$(BLA.AU)$</a> To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

March 26 (Reuters) - Savara Inc SVRA.O:

  • SAVARA COMPLETES SUBMISSION OF THE BIOLOGICS LICENSE APPLICATION (BLA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR MOLBREEVI* AS A TREATMENT FOR AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)

  • SAVARA INC - TO SUBMIT MOLBREEVI MAA IN EUROPE BY END OF 2025

  • SAVARA INC: COMMERCIAL PREPARATIONS ARE ON-TRACK TO SUPPORT A POTENTIAL LAUNCH IN EARLY 2026

Source text: ID:nBw6ZdRW0a

Further company coverage: SVRA.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10